Short Interest in Allarity Therapeutics, Inc. (NASDAQ:ALLR) Drops By 20.7%

Allarity Therapeutics, Inc. (NASDAQ:ALLR) was the target of a large drop in short interest in February. As of February 27th, there was short interest totaling 227,623 shares, a drop of 20.7% from the February 12th total of 287,071 shares. Based on an average daily volume of 138,739 shares, the short-interest ratio is currently 1.6 days. Approximately 1.4% of the shares of the stock are short sold. Approximately 1.4% of the shares of the stock are short sold. Based on an average daily volume of 138,739 shares, the short-interest ratio is currently 1.6 days.

Allarity Therapeutics Price Performance

Allarity Therapeutics stock opened at $1.26 on Monday. The company has a market cap of $20.26 million, a price-to-earnings ratio of -2.14 and a beta of 0.20. Allarity Therapeutics has a 12 month low of $0.61 and a 12 month high of $2.35. The stock’s 50-day moving average is $1.06 and its 200-day moving average is $1.26.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of ALLR. Private Advisor Group LLC acquired a new position in Allarity Therapeutics during the third quarter valued at approximately $441,000. Renaissance Technologies LLC increased its position in shares of Allarity Therapeutics by 274.1% in the fourth quarter. Renaissance Technologies LLC now owns 247,612 shares of the company’s stock worth $267,000 after acquiring an additional 181,426 shares in the last quarter. DRW Securities LLC acquired a new stake in shares of Allarity Therapeutics in the fourth quarter worth $133,000. Capital Advisors Inc. OK purchased a new position in shares of Allarity Therapeutics in the 4th quarter valued at $108,000. Finally, Citadel Advisors LLC purchased a new position in shares of Allarity Therapeutics in the 3rd quarter valued at $149,000. Hedge funds and other institutional investors own 11.53% of the company’s stock.

Analysts Set New Price Targets

A number of research firms recently issued reports on ALLR. Ascendiant Capital Markets upped their target price on Allarity Therapeutics from $9.25 to $9.50 and gave the company a “buy” rating in a research note on Tuesday, December 9th. Weiss Ratings reissued a “sell (e+)” rating on shares of Allarity Therapeutics in a research report on Wednesday, January 21st. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $9.50.

Allarity Therapeutics Company Profile

Allarity Therapeutics A/S (NASDAQ:ALLR) is a clinical‐stage biotechnology company focused on advancing precision medicine in oncology and other severe diseases. The company leverages predictive biomarkers and proprietary companion diagnostic tools to identify patient populations most likely to respond to its therapeutic candidates. By integrating molecular profiling early in development, Allarity aims to improve clinical trial success rates and accelerate the path to regulatory approval.

The company’s lead pipeline includes novel small‐molecule inhibitors engineered to target key pathways in solid tumors, with two primary assets currently in mid‐stage clinical trials.